PT  - JOURNAL ARTICLE
AU  - Warren, Jaime
TI  - Alternative Isotope Options for Amyloidosis Imaging: A Technologist’s Perspective
AID  - 10.2967/jnmt.122.264895
DP  - 2023 Jun 01
TA  - Journal of Nuclear Medicine Technology
PG  - 117--119
VI  - 51
IP  - 2
4099  - http://tech.snmjournals.org/content/51/2/117.short
4100  - http://tech.snmjournals.org/content/51/2/117.full
SO  - J. Nucl. Med. Technol.2023 Jun 01; 51
AB  - The recent pyrophosphate shortages can limit the availability of 99mTc-pyrophosphate scans for cardiac amyloidosis. However, another radiotracer is available: 99mTc-hydroxymethylene diphosphonate (HMDP). 99mTc-HMDP, widely available in the United States for bone scanning, has effectively been used in Europe to diagnose transthyretin amyloidosis. 99mTc-HMDP and 99mTc-pyrophosphate have comparable blood clearance and sensitivity. The imaging protocols for 99mTc-HMDP and 99mTc-pyrophosphate are similar, except 99mTc-HMDP is imaged 2–3 h after injection and whole-body imaging is optional. The interpretation is also essentially the same; however, caution is needed because of the high soft-tissue uptake with 99mTc-HMDP, which can affect heart–to–contralateral-lung ratios.